Decheng Capital Management III (Cayman)’s Roivant Sciences ROIV Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$17M	Buy	+1,459,700	New	+$16.5M	5.69%	4

Other funds holding ROIV

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s ROIV Position: Q3 2023 in Review

Decheng Capital Management III (Cayman) opened a new position in Roivant Sciences (ROIV) in Q3 2023: 1,459,700 shares worth $17M. The stake represents 5.69% of the portfolio and ranks #4 among its holdings.

205 funds tracked by Wall St. Rank hold ROIV as of Q3 2023.

Decheng Capital Management III (Cayman) held 1,459,700 shares of Roivant Sciences worth $17M as of Q3 2023.
Roivant Sciences was a new Decheng Capital Management III (Cayman) position in Q3 2023.
Roivant Sciences made up 5.69% of Decheng Capital Management III (Cayman)'s portfolio in Q3 2023, its #4 holding.
205 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.